Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

TCT 2021 | Haploidentical vs matched donor transplantation in patients with myelofibrosis

Tania Jain • 12 Feb 2021
TCT 2021
Myelofibrosis Myeloproliferative Neoplasms

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, provides an overview of the outcomes of haploidentical donor transplantation versus matched donor allogeneic hematopoietic cell transplantations in patients with myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Tania Jain

Changes in the duration of the monitoring period following CAR T-cell infusion 1:35
Changes in the duration of the monitoring period following CAR T-cell infusion
Tania Jain • 23 Aug 2025
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy 3:19
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy
Tania Jain • 23 Aug 2025
Immunotherapy in MPNs: antibodies, CAR-T, and more 2:31
Immunotherapy in MPNs: antibodies, CAR-T, and more
Tania Jain • 23 Aug 2025
Cellular therapy modalities being explored for the prevention of post-transplant relapse 3:15
Cellular therapy modalities being explored for the prevention of post-transplant relapse
Tania Jain • 24 Aug 2024

Related Videos

Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs 2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
Real-world treatment duration of ruxolitinib and transfusion use in patients with myelofibrosis 2:03
Real-world treatment duration of ruxolitinib and transfusion use in patients with myelofibrosis
Prithviraj Bose • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals